- Home
- CLSK vs AZTA Comparison
CLSK vs AZTA Comparison
Compare CLSK & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- AZTA
- Stock Information
- Founded
- CLSK 1987
- AZTA 1978
- Country
- CLSK United States
- AZTA United States
- Employees
- CLSK N/A
- AZTA N/A
- Industry
- CLSK Finance: Consumer Services
- AZTA Industrial Machinery/Components
- Sector
- CLSK Finance
- AZTA Technology
- Exchange
- CLSK Nasdaq
- AZTA Nasdaq
- Market Cap
- CLSK 1.9B
- AZTA 1.8B
- IPO Year
- CLSK N/A
- AZTA 1995
- Fundamental
- Price
- CLSK $7.51
- AZTA $25.25
- Analyst Decision
- CLSK Strong Buy
- AZTA Buy
- Analyst Count
- CLSK 7
- AZTA 3
- Target Price
- CLSK $22.00
- AZTA $57.00
- AVG Volume (30 Days)
- CLSK 27.2M
- AZTA 876.0K
- Earning Date
- CLSK 05-08-2025
- AZTA 05-07-2025
- Dividend Yield
- CLSK N/A
- AZTA N/A
- EPS Growth
- CLSK N/A
- AZTA N/A
- EPS
- CLSK 0.27
- AZTA N/A
- Revenue
- CLSK $467,488,000.00
- AZTA $662,108,000.00
- Revenue This Year
- CLSK $118.59
- AZTA N/A
- Revenue Next Year
- CLSK $36.65
- AZTA $5.44
- P/E Ratio
- CLSK $27.49
- AZTA N/A
- Revenue Growth
- CLSK 118.07
- AZTA 5.36
- 52 Week Low
- CLSK $6.45
- AZTA $25.36
- 52 Week High
- CLSK $21.39
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- CLSK 47.80
- AZTA 27.55
- Support Level
- CLSK $6.45
- AZTA $25.36
- Resistance Level
- CLSK $8.15
- AZTA $27.89
- Average True Range (ATR)
- CLSK 0.78
- AZTA 2.31
- MACD
- CLSK 0.06
- AZTA -0.23
- Stochastic Oscillator
- CLSK 62.49
- AZTA 5.13
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.